Literature DB >> 12270758

Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling.

Masaji Ishiguro1, Yukiyo Futabayashi, Toshio Ohnuki, Maruf Ahmed, Ikunobu Muramatsu, Takafumi Nagatomo.   

Abstract

This investigation was performed to assess the importance of interaction in the bindings of selective and nonselective alpha(1)-antagonists to alpha(1)-adrenergic receptor (alpha(1)-AR) subtypes using molecular modeling. The alpha(1)-antagonists used in this study were prazosin, tamsulosin and KMD-3213. Molecular modeling was performed on Octane 2 workstation (Silicon Graphics) using Discover/Insight II software (Molecular Simulations Inc.). Through molecular modeling, possible binding sites for these drugs were suggested to lie between transmembrane domains (TM) 3, 4, 5 and 6 of the alpha(1)-AR subtypes. In prazosin, the 4-amino group, 1-nitrogen atom and two methoxy groups of quinazoline ring possibly interact with the amino acids in TM3, TM5 and TM6 of alpha(1)-ARs. In tamsulosin, amine group of ethanyl amine chain, methoxy group of benzene ring and sulfonamide nitrogen of benzene ring interacts in TM3, TM4 and TM5 of alpha(1)-ARs. In KMD-3213, amine of ethyl amine chain and indoline nitrogen of this compound possibly interact within TM3 and TM5 of alpha(1)-ARs. Amide nitrogen of KMD-3213 also interacts within TM4 of alpha(1A)-AR. The results of the present study suggested that prazosin has similar binding sites in all the alpha(1)-AR subtypes while tamsulosin interacts at higher number of sites with alpha(1D)-subtype than other alpha(1)-AR subtypes. KMD-3213 being an alpha(1A)-AR selective ligand, binds to higher number of sites of alpha(1A) subtype than to other subtypes. All these amino acids are located near the extracellular loop. These findings are consistent with the previous studies that antagonists bind higher in the pocket closer to the extracellular surface unlike agonist binding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270758     DOI: 10.1016/s0024-3205(02)02077-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  Structure-function of alpha1-adrenergic receptors.

Authors:  Dianne M Perez
Journal:  Biochem Pharmacol       Date:  2006-09-16       Impact factor: 5.858

2.  Differential effects of 5-HT(2A) and 5-HT(2C) receptor blockade on strategy-switching.

Authors:  Phillip M Baker; Jennifer L Thompson; John A Sweeney; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2011-01-12       Impact factor: 3.332

3.  Computational studies of the binding site of alpha1A-adrenoceptor antagonists.

Authors:  Minyong Li; Hao Fang; Lupei Du; Lin Xia; Binghe Wang
Journal:  J Mol Model       Date:  2008-07-15       Impact factor: 1.810

Review 4.  Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.

Authors:  Masaki Yoshida; Junzo Kudoh; Yukio Homma; Kazuki Kawabe
Journal:  Clin Interv Aging       Date:  2011-06-22       Impact factor: 4.458

Review 5.  Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability.

Authors:  Hee Ju Cho; Tag Keun Yoo
Journal:  Res Rep Urol       Date:  2014-09-26

6.  The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the α1-adrenoceptor.

Authors:  D Nakladal; H Buikema; A Reyes Romero; S P H Lambooy; J Bouma; G Krenning; P Vogelaar; A C van der Graaf; M R Groves; J Kyselovic; R H Henning; L E Deelman
Journal:  Sci Rep       Date:  2019-01-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.